Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bolus dose of dexmedetomidine with S(+)-ketamine for drug-induced sleep endoscopy in pediatric obstructive sleep apnea
ChiCTR2100044299Phase 4Recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexmedetomidine and esketamine in obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Shanghai Children's Medical Center. Primary endpoint: 50% effective bolus dose. Started Mar 2021; status: recruiting.
02
Drugs
dexmedetomidineesketamine
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ChiCTR2100044299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044299.